Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.

Madhi, Shabir A; Moodley, Dhayendre; Hanley, Sherika; Archary, Moherndran; Hoosain, Zaheer; Lalloo, Umesh; Louw, Cheryl; Fairlie, Lee; Fouche, Leon Frederik; Masilela, Mduduzi SL; +38 more... Singh, Nishanta; Grobbelaar, Coert; Ahmed, Khatija; Benadé, Gabriella; Bhikha, Sutika; Bhorat, As'ad Ebrahim; Bhorat, Qasim; Joseph, Natasha; Dheda, Keertan; Esmail, Aliasgar; Foulkes, Sharne; Goga, Ameena; Oommen Jose, Aylin; Kruger, Gertruida; Kalonji, Dishiki J; Lalloo, Natasha; Lombaard, Johan J; Lombard Koen, Anthonet; Kany Luabeya, Angelique; Mngqibisa, Rosie; Petrick, Friedrich G; Pitsi, Annah; Tameris, Michele; Thombrayil, Asha; Vollgraaff, Pieter-Louis; Cloney-Clark, Shane; Zhu, Mingzhu; Bennett, Chijioke; Albert, Gary; Faust, Emmanuel; Plested, Joyce S; Fries, Lou; Robertson, Andreana; Neal, Susan; Cho, Iksung; Glenn, Greg M; Shinde, Vivek; 2019nCoV-501 Study Group; (2022) Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. The lancet. HIV, 9 (5). e309-e322. ISSN 2405-4704 DOI: https://doi.org/10.1016/S2352-3018(22)00041-8

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S2352-3018(22)00041-8

Abstract

Item Type Article
Faculty and Department Faculty of Infectious and Tropical Diseases > Department of Infection Biology
Research Centre Covid-19 Research
PubMed ID 35489376
Elements ID 177118

Share

Download

Filename: Immunogenicity_and_safety_of_a.pdf

Licence: Creative Commons: Attribution 4.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar